Navegando por Assunto "Helicobacter pylori"

Filtrar resultados informando as primeiras letras
Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Tratamento de gastrite associada à infecção por Helicobacter Pylori no Centro de Especialidades Médicas do CESUPA
    (Centro Universitário do Estado do Pará, 2019) Guerra, Andressa da Silva; Custódio, Sávio Sérgio Ferreira; Valente, Tárik Olívar de Nunes; http://lattes.cnpq.br/9516550105434600
    Objective: To describe the epidemiological profile and treatment of patients with gastritis associated with Helicobacter pylori infection treated at CESUPA's Medical Specialties Center (CEMEC). Method: The cross-sectional descriptive study was carried out at the Center of Medical Specialties (CEMEC) of the University Center of Pará (CESUPA), from August 2018 to February 2019, where 352 medical records of patients regularly enrolled in the CEMEC’s Gastroenterology service during the first half of 2016 until the first half of 2018 were analyzed. Data collection was done according to the Data Collection Research Protocol. Results: In this series, the majority of the patients were female (80%). This study revealed that the majority of patients were concentrated in the age group between 51 and 70 years. Triple therapy with amoxicillin, clarithromycin, and pantoprazole was the most widely used regimen in this study, considering that all patients who tested positive for H. pylori infection were treated. It was observed that about 6% of patients started treatment with levofloxacin, clarithromycin and proton pump inhibitor (PPI). The vast majority of patients did not require retreatment (76.7%), but those who needed it were treated with levofloxacin, amoxicillin and proton pump inhibitor. Conclusion: There was a predominance of gastritis associated with Helicobacter pylori infection in women and in the population between 51 and 70 years. Regarding therapy of choice, the regimen with amoxicillin, clarithromycin and pantoprazole was the most used. The need for retreatment was identified in 23.3% of the patients, with levofloxacin, clarithromycin and PPI being the choice for these patients (66.7%).